They verified that in patient-derived breast cancer organoids, HELA-Exos significantly enhanced the generation of conventional type 1 dendritic cells(cDC1) antigen cross-presentation and tumor-reactive CD8+ T cells, indicating that HELA-Exos exhibits potent antitumor activity in breast cancer (80). This evidence concerns the gene CD8A and breast carcinoma.